Publications by authors named "Danielle Brander"

Claim this Profile
R
Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.
Danielle M Brander, Andrew W Roberts, Thomas J Kipps, Shuo Ma, Mary Ann Anderson

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refitting fitness in CLL.
Danielle M Brander

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era.
Cecelia R Miller, Ying Huang, John N Allan, Seema A Bhat, David Bond, Danielle Brander

Am J Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy.
Mohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, Jennifer R Brown, Mazyar Shadman, Danielle M Brander

Transplant Cell Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R Brown, Brad S Kahl, Danielle Brander

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia.
Akash Roy, Danielle M Brander, Elizabeth G Hill, Susan Halabi

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
Matthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, Catherine S Diefenbach, Daniel N Egan

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry.
Cecilia Bonolo de Campos, Chantal E McCabe, Laura A Bruins, Daniel R O'Brien, Sochilt Brown, Danielle M Brander

Blood Cancer J· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.
Adam S Kittai, Ying Huang, Sarah Miller, John N Allan, Seema A Bhat, Danielle M Brander

Blood Cancer J· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Back from (BTKi) holiday.
Danielle M Brander, Andrea Sitlinger

Blood Adv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis.
Geffen Kleinstern, Nicholas J Boddicker, Daniel R O'Brien, Cristine Allmer, Kari G Rabe, Danielle M Brander

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Jennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Danielle M Brander

Blood· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
William G Wierda, Jennifer Brown, Jeremy S Abramson, Farrukh Awan, Syed F Bilgrami, Danielle Brander

J Natl Compr Canc Netw· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
Inhye E Ahn, Danielle M Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry.
Anthony R Mato, Nilanjan Ghosh, Jeff P Sharman, Danielle Brander, Meghan Gutierrez

Blood Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Tanya Siddiqi, David G Maloney, Saad S Kenderian, Danielle M Brander, Kathleen Dorritie

Lancet· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan, Danielle M Brander

Clin Lymphoma Myeloma Leuk· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Scott F Huntington, Stephen J Schuster, Wei Ding, Amber B Koehler, Danielle M Brander

Am J Hematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Christine E Ryan, Danielle M Brander, Paul M Barr, Svitlana Tyekucheva, Liam R Hackett

Leukemia· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: A pilot study.
Ashley L Artese, Andrea Sitlinger, Grace MacDonald, Michael A Deal, Erik D Hanson, Danielle M Brander

J Geriatr Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of zanubrutinib in chronic lymphocytic leukemia.
Danielle M Brander

Clin Adv Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Constantine S Tam, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Krzysztof Giannopoulos, Danielle M Brander

Lancet Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations of clinical and circulating metabolic biomarkers with low physical fitness and function in adults with chronic lymphocytic leukemia.
Andrea Sitlinger, Michael A Deal, Erwin Garcia, Margery Connelly, Dana Thompson, Danielle Brander

Front Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
William G Wierda, Jennifer Brown, Jeremy S Abramson, Farrukh Awan, Syed F Bilgrami, Danielle Brander

J Natl Compr Canc Netw· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.
Rachel Hu, Wei Wei, Agrima Mian, Kristen Gonter-Aubin, Charlene Kabel, Danielle Brander

Eur J Haematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis